collaboration

Preparing for a post-pandemic world

Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the pandemic. There’s plenty of talk about a post-COVID world right now, which can seem strange when so many places are still feeling the impact or remain in the grip of …

Preparing for a post-pandemic world Read More »

Trinity Health Mid-Atlantic to deploy NeuroFlow’s mental health tools across 3 hospitals

Through a program funded by Independence Blue Cross Foundation, 1,800 frontline healthcare workers across the three Pennsylvania-based hospitals will gain access to NeuroFlow’s technology, which will measure and track their mental health symptoms and provide support via educational resources and a clinical care team.

CareMax to add 50 new senior care centers through Anthem collaboration

The senior care provider currently operates 34 medical centers offering healthcare and social services, like transportation. Through the collaboration, the companies will bring more seniors into value-based arrangements with the goal of improving outcomes for Anthem patients.

HIMSS Digital: Future is bright for payer-provider-pharma collaboration

The pandemic made collaboration necessary between stakeholders that otherwise tend to be at odds with each other. But as partnerships grow, providers, payers and pharma companies must ensure they are working toward a clear-cut common goal, according to panelists at HIMSS 21 Digital.

Overcoming barriers to healthcare innovation to improve provider engagement and patient outcomes

Virtual care delivery can offer increased convenience and accessibility for patients. But the larger challenge is laying a foundation for innovation in health systems that enables providers to optimize their workflows and collaborate more effectively—ultimately improving patient care.

Report: Which US markets are ripe for ‘payvider’ models? 

“Payvider” models — that is, collaborative arrangements between payers and providers — are growing in popularity. But not all markets are created equal with regard to payvider adoption and growth. In a new report, consultancy firm Guidehouse identifies the markets with the most opportunities for payviders.

UnitedHealthcare’s new social determinants effort spans 23 programs

The payer’s Community Catalyst initiative includes 23 programs that involve collaborations with various community-based organizations and health centers. They tackle different types of social determinants of health issues, including food insecurity among seniors and the health needs of those in public housing.

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia

Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 Vertex will be responsible for 60% of program costs and will receive 60% of profits from future sales of CTX001 globally, representing a 10% increase …

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia Read More »

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC The expanded agreement allows the partners …

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer Read More »

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2, wq, IV) for P- I/IIa trial in NSCLC …

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC Read More »

Preparing for a New Age without Information Blocking

Digital technologies have become prevalent in healthcare after the passage of the Health Information Technology for Economic and Clinical Health (HITECH) Act in 2009. Though we have seen adoption and meaningful use of technology in at least 96% of the hospitals in the United States, electronic access to health information is stymied. What is Information …

Preparing for a New Age without Information Blocking Read More »

Merck KGaA Selects PRA’s Remote Patient Monitoring Platform for Human Growth Hormone Treatment System

Shots: Merck KGaA selects PRA’s remote patient monitoring platform to work in combination with its HGH treatment system PRA’s remote patient monitoring platform will support Merck’s KGH system including its growlink (mobile app) and easypod connect (HCP platform) to monitor patient adherence, review injection history, and share information about the progress of patients with GHD …

Merck KGaA Selects PRA’s Remote Patient Monitoring Platform for Human Growth Hormone Treatment System Read More »

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management technology into Lilly’s connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc’s BlueStar app which will be …

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App Read More »

Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration Merck KGaA exercises its third option to develop an additional bispecific program under the ongoing collaboration with F-star Merck KGaA will be responsible for the development and commercialization of the …

Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star Read More »

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company’s agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company’s TATs platform & Fast-Clear linker technology and provide a glance at Fusion’s portfolio. Shots: Fusion to receive $5M up front and $40M as …

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca Read More »

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH

Shots: The companies plan to initiate a P-IIb study assessing NovoNordisk’s semaglutide and FD combination of Gilead’s cilofexor + firsocostat vs PBO in ~440 patients with compensated cirrhosis (F4) due to NASH The trial will evaluate the therapeutic effect on liver fibrosis improvement and NASH resolution and expected to initiate recruitment in H2’21 The new …

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH Read More »

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH

Shots: The companies plan to initiate a P-IIb study assessing NovoNordisk’s semaglutide and FD combination of Gilead’s cilofexor + firsocostat vs PBO in ~440 patients with compensated cirrhosis (F4) due to NASH The trial will evaluate the therapeutic effect on liver fibrosis improvement and NASH resolution and expected to initiate recruitment in H2’21 The new …

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH Read More »

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety …

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework Read More »

Mayo Clinic, Google eyeing ‘AI factory’ as collaboration moves forward

The health system and tech giant are more than a year into their 10-year collaboration. As their partnership evolves, the organizations are looking to create an “AI factory” — an assembly line of AI solutions that are developed at scale and incorporated into clinical workflows.

Kaiser Permanente joins forces with Accenture, Microsoft to improve cloud capabilities

The California-based healthcare organization will work with Accenture and Microsoft to grow and strengthen its cloud capabilities. The enhancements are expected to help Kaiser provide its care teams with data insights to personalize patient care.

Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive …

Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets Read More »

Healthcare Now – What’s Next in the Americas

With the new year underway, we are excited and encouraged by the new COVID-19 vaccines being deployed to healthcare workers and high-risk individuals in the United States and Canada. Here in the United States, each of our states are receiving their allocated commitments of vaccinations and planning is underway for broad-scale deployment of the vaccine. …

Healthcare Now – What’s Next in the Americas Read More »

Fine-tuning telehealth, addressing mental health take precedence for providers in 2021

As 2020 draws to a close, healthcare providers are strategizing for the new year and the new normal. Providers will need to retool their telehealth efforts and prepare to meet a burgeoning mental crisis, among other issues.

How Webex Uses Patient and Provider Insight to Improve Virtual Care Delivery

Follow along with our blog series #HealthcareNow and #PublicSectorNow, where we’ll address healthcare innovation around the world and how to maintain business continuity in today’s health climate.  In the past few months, we’ve seen huge shifts in how people are working. This naturally extends to the healthcare industry, where care delivery continues to be a priority, even amidst …

How Webex Uses Patient and Provider Insight to Improve Virtual Care Delivery Read More »

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio …

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China Read More »

GSK Signs an Agreement with Vir Biotechnology to Develop Solutions for Coronaviruses

Shots: GSK will make equity investment to gain access to Vir’s technology of $250M, priced at $37.73 (a 10% premium to closing share price on March 27, 2020). The equity investment and collaboration will complete at the same time & are conditional upon customary conditions including regulatory review by appropriate regulatory agencies under Hart-Scott-Rodino Act …

GSK Signs an Agreement with Vir Biotechnology to Develop Solutions for Coronaviruses Read More »

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

Shots:   Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights.  The companies will form a joint development committee to manage clinical study which is anticipated to commence in H1’21 The focus of the collaboration …

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma Read More »

Georgia Department of Public Health: Keeping Doctors and Patients Connected

Follow along with our new blog series #HealthcareNow and #PublicSectorNow, where we’ll addresses healthcare innovation around the world and how to maintain business continuity in today’s health climate.  Georgia Department of Public Health (DPH) needed a way to continue critical healthcare services without in-person visits when the pandemic hit.  Like most healthcare organizations, they needed to pivot when stay at home …

Georgia Department of Public Health: Keeping Doctors and Patients Connected Read More »

Evotec and Centogene Expand their Collaboration to Target Gaucher Disease

Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows …

Evotec and Centogene Expand their Collaboration to Target Gaucher Disease Read More »

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to evaluate use of its lead molecule tigilanol tiglate, in combination with Keytruda(R) (pembrolizumab) in patients with unresectable …

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma Read More »

Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19

Shots: Eli Lilly initiates P-III BLAZE-2 study assessing LY-CoV555 to prevent SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the US (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities) The company will enroll up to ~2400 patients and test whether a single dose of LY-CoV555 …

Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19 Read More »

DuPont Announces Research Collaboration with Rutgers University

DuPont Nutrition & Biosciences (DuPont) today announced a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University in New Jersey. The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation …

DuPont Announces Research Collaboration with Rutgers University Read More »

Roche Signs RWD Collaboration with PicnicHealth to Create Personalized Treatment for Patients with Multiple Sclerosis

Shots: The real-world evidence partnership will allow the Roche to access PicnicHealth’s set of de-identified patient records to gain insights on certain diseases and treatments The collaboration will initially focus on MS and may be extended to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia The companies signed a multi-year collaboration that combines …

Roche Signs RWD Collaboration with PicnicHealth to Create Personalized Treatment for Patients with Multiple Sclerosis Read More »

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star

Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star Merck KGaA will be responsible for the development and commercialization of the preclinical program …

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star Read More »

5 Ways RWE is Fueling the Fight Against COVID-19

As we discussed in an earlier blog post, real-world evidence can bring value to every stage of the drug life cycle, from early discovery to post-market. Now, as the worldwide research community continues to battle the COVID-19 pandemic, we are also discovering how real-world data and real-world evidence have something to offer in these efforts …

5 Ways RWE is Fueling the Fight Against COVID-19 Read More »